Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

50.99 +0.38 (+0.75%)
Streaming Delayed Price Updated: 10:18 AM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 Next >
Why Ionis Pharmaceutical Shares Are Trading Lower Wednesday
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading lower on Wednesday after the company announced plans to offer $500 million of senior convertible notes due in 2028 in a private placement... 
Via Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79
The Relative Strength Rating for Ionis Pharmaceuticals stock moved into a new percentile Wednesday, as it got a lift from 65 to 79. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
Via Benzinga
Recap: Ionis Pharmaceuticals Q1 Earnings
Via Benzinga
Ionis Pharmaceuticals's Earnings Outlook
Via Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
Analyst Ratings for Ionis Pharmaceuticals
Via Benzinga
Ionis Pharmaceuticals's Earnings Outlook
Via Benzinga
Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA
The FDA approved Biogen Inc's (NASDAQ: 
Via Benzinga
What's Going On With Biogen Stock Tuesday?
Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.  
Via Benzinga
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs
Via Benzinga
3 Biotech Stocks to Sell Before They’re 6 Feet Under
Biotech stocks with no earnings, no cash, and no path to profit will have no chance at survival. Here's three such biotech stocks to avoid. 
Via InvestorPlace
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
Via Benzinga
Could This Rare-Disease Drug Candidate Become a Blockbuster?
This drug candidate could be a great treatment option for patients with a potentially deadly disease. 
Via The Motley Fool
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
The Latest Analyst Ratings for Ionis Pharmaceuticals
Via Benzinga
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy... 
Via Benzinga
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
Via Benzinga
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
The companies are focusing on a small population of ALS patients with a genetic mutation. 
Via Investor's Business Daily
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
Via Benzinga
Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile'
Via Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
From Royalty Pharma plc
Via GlobeNewswire
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
From Biogen Inc.
Via GlobeNewswire
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.